Loading…
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 2.47% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 0% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 0% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0% of any dividend from ONESOURCE should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
ONESOURCE shows mixed signals with a negative 1-month return, modestly positive 3-month performance, slightly negative 6-month return, and the 50-day above the 200-day, suggesting a choppy consolidation around an underlying upward-leaning structure. The stock is well off its 52-week high, reinforcing the sense of a sideways, corrective phase.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.